# Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer

> **NCT00786006** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 61 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** FOLFIRI.3
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT00786006
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-03
- **Final completion:** 2009-09
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2011-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00786006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00786006, "Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00786006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*